Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172


The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group.

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.


Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group.

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.


Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.


Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.

Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group.

Chest. 2013 Sep;144(3):990-998. doi: 10.1378/chest.12-2820.


Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms.

Jung C, Colombel JF, Lemann M, Beaugerie L, Allez M, Cosnes J, Vernier-Massouille G, Gornet JM, Gendre JP, Cezard JP, Ruemmele FM, Turck D, Merlin F, Zouali H, Libersa C, Dieudé P, Soufir N, Thomas G, Hugot JP.

PLoS One. 2012;7(12):e52223. doi: 10.1371/journal.pone.0052223. Epub 2012 Dec 27.


Risk factors of anxiety and depression in inflammatory bowel disease.

Nahon S, Lahmek P, Durance C, Olympie A, Lesgourgues B, Colombel JF, Gendre JP.

Inflamm Bowel Dis. 2012 Nov;18(11):2086-91. doi: 10.1002/ibd.22888. Epub 2012 Jan 31.


Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.


Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.


Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey.

Nahon S, Lahmek P, Saas C, Durance C, Olympie A, Lesgourgues B, Gendre JP.

Inflamm Bowel Dis. 2011 Jun;17(6):1270-6. doi: 10.1002/ibd.21482. Epub 2010 Oct 25.


Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.

Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, Baumer P, Cosnes J, Bourreille A, Gendre JP, Seksik P, Blain A, Metman EH, Nisard A, Cadiot G, Veyrac M, Coffin B, Dray X, Carrat F, Marteau P; CESAME Pregnancy Study Group (France).

Gut. 2011 Feb;60(2):198-203. doi: 10.1136/gut.2010.222893. Epub 2010 Nov 29.


Results of a national survey on quality of life in inflammatory bowel diseases.

Lesage AC, Hagège H, Tucat G, Gendre JP.

Clin Res Hepatol Gastroenterol. 2011 Feb;35(2):117-24. doi: 10.1016/j.gcb.2009.08.015. Epub 2010 Oct 30.


Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group.

Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7.


Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine.

Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L.

Aliment Pharmacol Ther. 2009 May 15;29(10):1106-13. doi: 10.1111/j.1365-2036.2009.03973.x. Epub 2009 Feb 15.


Hot-water bottle syndrome.

Zeitoun JD, Bourrier A, Gendre JP.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):A24. Epub 2007 Oct 29. No abstract available.


Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up.

Poupardin C, Lémann M, Gendre JP, Sabaté JM, Marteau P, Chaussade S, Delchier JC, Bouhnik Y, Chaput JC, Poupon R, Soulé JC, Benhamou Y, Grangé JD, Coffin B.

Gastroenterol Clin Biol. 2006 Feb;30(2):247-52.


Prior appendectomy and the phenotype and course of Crohn's disease.

Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP.

World J Gastroenterol. 2006 Feb 28;12(8):1235-42.


Predictors of Crohn's disease.

Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J.

Gastroenterology. 2006 Mar;130(3):650-6.


Intestinal perforation in Crohn's disease. Factors predictive of surgical resection.

Brihier H, Nion-Larmurier I, Afchain P, Tiret E, Beaugerie L, Gendre JP, Cosnes J.

Gastroenterol Clin Biol. 2005 Nov;29(11):1105-11.


A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.

Gut. 2006 Aug;55(8):1138-44. Epub 2006 Feb 21.


Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.

Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre JP, Grange JD, Houry S, Talbot JN.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):340-5.


Supplemental Content

Loading ...
Support Center